Trial Profile
A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept
- Sponsors XBiotech
- 12 Nov 2019 According to a XBiotech media release, data from this trial were presented at the European Academy of Dermatology and Venereology (EADV) Congress
- 27 Sep 2019 Results presented in the XBiotech media release.
- 27 Sep 2019 According to a XBiotech media release, data from this trial will be presented at the European Academy of Dermatology and Venereology (EADV) Congress being held in Madrid Spain October 9-13th 2019.